ESR1 and breast carcinoma: In another study, the CellSearch® and DEPArrayTM systems were combined in order to isolate single CTCs from ER-positive metastatic breast cancer patients; using MALBAC and Sanger Sequencing, 14 ESR1 hotspot mutations were detected, and their presence was correlated with endocrine resistance [45].